Vaccines: Spinning molecular immunology into successful immunotherapy

Until recently, immunotherapies have been of limited success, particularly against cancer. However, recent insights into the cells, molecules and signalling pathways that regulate immune responsiveness are providing new approaches for immunotherapy. In this article, I review some of the most promising molecular and cellular targets for immunotherapy and discuss approaches that use these targets to amplify immune responses and potentially break antigen-specific tolerance. These strategies provide a blueprint for the development of successful immunotherapy over the next decade.

[1]  G. Klein,et al.  Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx , 1970, Nature.

[2]  C. Mckhann,et al.  ANTIGENIC SPECIFICITIES ON MURINE SARCOMA CELLS , 1971, The Journal of experimental medicine.

[3]  W. Szmuness Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. , 1978, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

[4]  D. Shafritz,et al.  Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. , 1981, The New England journal of medicine.

[5]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[6]  W. Bodmer,et al.  Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines. , 1982, National Cancer Institute monograph.

[7]  C. Bréchot [What is the role of hepatitis B virus in the appearance of hepatocellular carcinomas in patients with alcoholic cirrhosis?]. , 1982, Gastroenterologie clinique et biologique.

[8]  S. Davis,et al.  Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Moss,et al.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[10]  F. Grosveld,et al.  Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation , 1984, Nature.

[11]  K. Münger,et al.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. , 1989, The EMBO journal.

[12]  R. Warnke,et al.  Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. , 1989, The New England journal of medicine.

[13]  T. Wu,et al.  Detection of ebv gene expression in reed‐sternberg cells of Hodgkin's disease , 1990, International journal of cancer.

[14]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[15]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Galloway,et al.  Characterization of the humoral immune response to genital papillomaviruses. , 1990, Molecular biology & medicine.

[17]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[18]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[19]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[20]  J. Banchereau,et al.  GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.

[21]  A. Harris,et al.  Loss of HLA class‐I alleles, heavy chains and β2‐microglobulin in colorectal cancer , 1992, International journal of cancer.

[22]  M. Perkus,et al.  Highly attenuated poxvirus vectors. , 1992, AIDS research and human retroviruses.

[23]  R. Steinman,et al.  Identification of proliferating dendritic cell precursors in mouse blood , 1992, The Journal of experimental medicine.

[24]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[25]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[26]  R. Levy,et al.  Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.

[27]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Thorsby,et al.  p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) , 2007, International journal of cancer.

[29]  J. Banchereau,et al.  Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.

[30]  P. Srivastava,et al.  Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. , 1994, Journal of immunology.

[31]  E. Thorsby,et al.  A K‐ras 13GLY → ASP mutation is recognized by HLA‐DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? , 1994, International journal of cancer.

[32]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[33]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[34]  M. Davis,et al.  T-cell recognition of antigen. A process controlled by transient intermolecular interactions. , 1995, Annals of the New York Academy of Sciences.

[35]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[36]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Pardoll,et al.  A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours , 1995, Nature Medicine.

[38]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[40]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[41]  E. Paoletti,et al.  Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. , 1995, Developments in biological standardization.

[42]  H. Rammensee,et al.  Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.

[43]  J. Sadoff,et al.  Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization , 1995, Science.

[44]  Mark M. Davis,et al.  T‐Cell Recognition of Antigen , 1995 .

[45]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[46]  Michael D. Roth,et al.  Human CD14+ leukocytes acquire the phenotype and function of antigen‐presenting dendritic cells when cultured in GM‐CSF and IL‐4 , 1996, Journal of leukocyte biology.

[47]  R. Steinman,et al.  Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.

[48]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[49]  E. Maraskovsky,et al.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.

[50]  P. Robbins,et al.  Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.

[51]  B. Moss Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[53]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[54]  D. Pardoll,et al.  Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? , 1996, The Journal of experimental medicine.

[55]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[56]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[57]  B. Bogen Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma , 1996, European journal of immunology.

[58]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[60]  G. Schuler,et al.  Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. , 1997, Advances in experimental medicine and biology.

[61]  B. Moss,et al.  Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. , 1997, Vaccine.

[62]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[63]  Özlem Türeci,et al.  SSX: A multigene family with several members transcribed in normal testis and human cancer , 1997, International journal of cancer.

[64]  J. Berzofsky,et al.  Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.

[65]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[66]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[67]  D. Kufe,et al.  Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.

[68]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[69]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[70]  S. Rafii,et al.  Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.

[71]  P. Srivastava,et al.  Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.

[72]  A. Chalian,et al.  Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes , 1997, Nature Biotechnology.

[73]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[74]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[75]  S. Rosenberg,et al.  Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.

[76]  N. Bhardwaj,et al.  A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. , 1997, Blood.

[77]  K. Timmis,et al.  Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium , 1997, Cell.

[78]  R. Young,et al.  Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Steinman,et al.  Developmental regulation of MHC class II transport in mouse dendritic cells , 1997, Nature.

[80]  J. Brady,et al.  Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction , 1998, Nature.

[81]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[82]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[83]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[84]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[85]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[87]  H. Youn,et al.  Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. , 1998, Immunity.

[88]  J. Becker,et al.  Immunocytokines: a promising approach to cancer immunotherapy. , 1998, Pharmacology & therapeutics.

[89]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[92]  M. Colombo,et al.  Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response , 1999, The Journal of experimental medicine.

[93]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  R. Kurman,et al.  Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. , 1999, Human gene therapy.

[95]  A. Chalian,et al.  CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. , 1999, Journal of immunology.

[96]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  D. Spriggs,et al.  Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. , 1999, Current topics in microbiology and immunology.

[98]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[99]  P. Pouwels,et al.  Live bacterial delivery systems for development of mucosal vaccines. , 2000, Current opinion in molecular therapeutics.

[100]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[101]  G. Lewis,et al.  Recent advances with recombinant bacterial vaccine , 2000 .

[102]  R. Steinman,et al.  The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments , 2000, The Journal of cell biology.

[103]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[104]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.

[105]  M. Tremblay,et al.  The T-cell protein tyrosine phosphatase. , 2000, Seminars in immunology.

[106]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[107]  G. Lewis,et al.  Recent advances with recombinant bacterial vaccine vectors. , 2000, Molecular medicine today.

[108]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[109]  H. Nishina,et al.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b , 2000, Nature.

[110]  J. Rothman,et al.  Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways , 2000, The Journal of experimental medicine.

[111]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[112]  E. Shevach,et al.  Cbl-b regulates the CD28 dependence of T-cell activation , 2000, Nature.

[113]  C. Klein,et al.  Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines , 2000, The Journal of experimental medicine.

[114]  A. Ramsay,et al.  The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.

[115]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  R. Barth,et al.  Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens , 2001, Journal of immunotherapy.

[117]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[118]  H. Ploegh,et al.  Virus subversion of immunity: a structural perspective. , 2001, Current opinion in immunology.

[119]  S. Chen,et al.  Targeting dendritic cells to enhance DNA vaccine potency. , 2001, Cancer research.

[120]  T. Wu,et al.  Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen1 , 2001, The Journal of Immunology.

[121]  P. Srivastava,et al.  CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.

[122]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[123]  J. Mulé,et al.  Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. , 2001, Cancer research.

[124]  T. Ratliff,et al.  Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors , 2001, International journal of cancer.

[125]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[126]  R. Issels,et al.  The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors , 2001, European journal of immunology.

[127]  C. Lowenstein,et al.  Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. , 2001, Cancer research.

[128]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  T. Wu,et al.  Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. , 2001, Cancer research.

[130]  Larry R. Smith,et al.  Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. , 2001, Cancer research.

[131]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[132]  C Crimi,et al.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.

[133]  E. Repasky,et al.  Characterization of Heat Shock Protein 110 and Glucose-Regulated Protein 170 as Cancer Vaccines and the Effect of Fever-Range Hyperthermia on Vaccine Activity1 , 2001, The Journal of Immunology.

[134]  M. Sadelain,et al.  Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. , 2001, Blood.

[135]  Tomas Mustelin,et al.  Activation of the Cooh-Terminal Src Kinase (Csk) by Camp-Dependent Protein Kinase Inhibits Signaling through the T Cell Receptor , 2001, The Journal of experimental medicine.

[136]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[137]  D. Hilton,et al.  Negative regulation of cytokine signaling , 2001, Journal of leukocyte biology.

[138]  N. Ohara,et al.  Recombinant BCG vaccines. , 2001, Vaccine.

[139]  M. Croft,et al.  Signaling through OX40 (CD134) breaks peripheral T-cell tolerance , 2001, Nature Medicine.

[140]  P. Srivastava Roles of heat-shock proteins in innate and adaptive immunity , 2002, Nature Reviews Immunology.